Nabriva Therapeutics plc
NBRVF · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | 0.01 |
| FCF Yield | 16.65% | -184.84% | -55.31% | -241.88% |
| EV / EBITDA | -0.12 | -0.21 | 0.19 | 0.55 |
| Quality | ||||
| ROIC | 77.93% | 244.73% | -251.73% | -36.28% |
| Gross Margin | -252.53% | 41.53% | -56.61% | 49.73% |
| Cash Conversion Ratio | -0.04 | 0.65 | 0.07 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 33.01% | 96.44% | 131.79% | 216.09% |
| Free Cash Flow Growth | 109.09% | -244.00% | 73.98% | 52.07% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | 0.15 | 0.32 | 0.79 |
| Interest Coverage | 0.00 | -43.69 | -160.65 | -76.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.49 | 1.69 | 0.25 |
| Cash Conversion Cycle | 16.09 | 166.18 | 81.49 | 400.80 |